| 000 | 01874 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515063319.0 | ||
| 264 | 0 | _c20070621 | |
| 008 | 200706s 0 0 eng d | ||
| 022 | _a1524-9557 | ||
| 024 | 7 |
_a10.1097/01.cji.0000211346.19330.c9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFriebe, Astrid | |
| 245 | 0 | 0 |
_aPretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. _h[electronic resource] |
| 260 |
_bJournal of immunotherapy (Hagerstown, Md. : 1997) _cApr 2007 |
||
| 300 |
_a333-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aDepression _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 |
_aInterleukin-4 Receptor alpha Subunit _xblood |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeopterin _xblood |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aReceptors, Interleukin-6 _xblood |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor, Type I _xblood |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aTh1 Cells _ximmunology |
| 650 | 0 | 4 |
_aTh2 Cells _ximmunology |
| 700 | 1 | _aSchwarz, Markus J | |
| 700 | 1 | _aSchmid-Wendtner, Monika | |
| 700 | 1 | _aVolkenandt, Matthias | |
| 700 | 1 | _aSchmidt, Folkhart | |
| 700 | 1 | _aHorn, Martin | |
| 700 | 1 | _aJanssen, Gesa | |
| 700 | 1 | _aSchaefer, Martin | |
| 773 | 0 |
_tJournal of immunotherapy (Hagerstown, Md. : 1997) _gvol. 30 _gno. 3 _gp. 333-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.cji.0000211346.19330.c9 _zAvailable from publisher's website |
| 999 |
_c16966088 _d16966088 |
||